Syndax Pharmaceuticals stock price target raised to $29 by BofA

BofA Securities raised Syndax Pharmaceuticals’ price target to $29 from $28 and reiterated a Buy rating, implying upside from the current $21.43 share price. The company also reported Q1 2026 EPS of -$0.48 versus -$0.62 expected, a 22.58% beat, though revenue missed at $64.9 million versus $71.84 million consensus. Management remains confident on the Revuforj rollout, with Axatilimab seen as a potential additional upside driver.

Analysis

SNDX is increasingly a launch-execution story rather than a pure science story, and that matters because the market is likely to reward visible commercial discipline before it fully believes the long-duration opportunity. The near-term setup favors the incumbent share-price path staying supported as long as uptake remains linear, but the stock will likely need evidence of first-line penetration before the market re-rates the franchise on terminal economics. That creates a classic “good-but-not-good-enough” window where upside is driven by cadence of prescription growth, not headline revenue alone.

The more interesting second-order effect is competitive: if KURA’s rollout stumbles even modestly, the market may infer that the menin category is harder to scale than investors expect, which would widen the perceived moat for the better-executing commercial team. Conversely, if both launches proceed well, the category may expand, but reimbursement friction and physician concentration can keep the winner-take-most narrative from fully playing out until 2027–2028. Axatilimab is the cleaner optionality driver because it diversifies the valuation away from a single launch curve and can cushion the stock if menin enthusiasm fades.

The main risk is that consensus is over-anchoring on medium-term launch upside while underestimating the time it takes for specialty oncology products to convert early awareness into durable line-share. The revenue miss versus expectations suggests the market may still be ahead of the commercial curve, which leaves room for volatility if quarterly sell-through or new patient starts decelerate. On the flip side, the EPS beat implies operating leverage is improving faster than topline perception, so the stock can grind higher even without a clean revenue inflection if expense discipline remains intact.

Key Decisions for Investors

• Stay long SNDX into the next 1-2 quarters, but size as a momentum-with-fundamentals trade rather than a full-duration thesis; target 10-15% upside toward consensus revisions, with a stop if launch metrics flatten for two reporting periods.
• Pair long SNDX / short KURA for the next 1-3 months to express relative execution risk in menin rollout; thesis works best if channel checks show faster prescription conversion for SNDX and should be covered if KURA begins to narrow the launch gap.
• Buy SNDX call spreads 3-6 months out to capture upside from continued commercial de-risking while limiting downside to the event that revenue remains below Street expectations; best risk/reward if implied volatility stays elevated around earnings.
• Add on pullbacks only if the stock trades below the current post-earnings support zone on no negative launch data; that gives a better entry than chasing strength because the re-rating is likely to be stair-step, not linear.
• Treat axatilimab as the longer-dated convexity driver and hold core exposure through the next data/update cycle; if the market starts to price it as a real second asset, SNDX can re-rate beyond a single-product multiple.